CHGCF (Chugai Pharmaceutical Co) Total Liabilities : $1,954 Mil (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Total Liabilities?

Chugai Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 was $1,954 Mil.

Chugai Pharmaceutical Co's quarterly Total Liabilities declined from Dec. 2023 ($2,131.99 Mil) to Mar. 2024 ($1,706.84 Mil) but then increased from Mar. 2024 ($1,706.84 Mil) to Jun. 2024 ($1,954.09 Mil).

Chugai Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 ($3,080.63 Mil) to Dec. 2022 ($3,301.13 Mil) but then declined from Dec. 2022 ($3,301.13 Mil) to Dec. 2023 ($2,131.99 Mil).

Chugai Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Chugai Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Total Liabilities Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,878.35

2,461.53

3,080.63

3,301.13

2,131.99

Chugai Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,911.85	2,131.99	1,706.84	1,954.09	-

Chugai Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Chugai Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2001.764	+	(0	+	108.375
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	21.85)
	=	2,132

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	13422.19	-	11290.2
	=	2,132

Chugai Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1837.958	+	(0	+	91.112
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	25.016)
	=	1,954

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	13050.57	-	11096.484
	=	1,954

Chugai Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CHGCY:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.